Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Dec;4(2):509-513.
doi: 10.1007/s40744-017-0084-0. Epub 2017 Oct 11.

A Case of Recalcitrant Psoriatic Arthritis to TNF Inhibitors Improved After Administration of Secukinumab, an IL-17A Inhibitor

Eleftherios Pelechas  1 , Tereza Memi  1 , Paraskevi V Voulgari  1 , Alexandros A Drosos  2
Affiliations

A Case of Recalcitrant Psoriatic Arthritis to TNF Inhibitors Improved After Administration of Secukinumab, an IL-17A Inhibitor

Eleftherios Pelechas et al. Rheumatol Ther. 2017 Dec.

Abstract

Psoriatic arthritis (PsA) is a unique inflammatory arthritis due to the fact that patients have to deal not only with pain but also with their skin appearance, which may have a detrimental effect on their everyday lives and psychology. Treating a patient with PsA, improving both the musculoskeletal and skin symptoms is a challenge for the clinical rheumatologist. In this case, we present a patient of recalcitrant PsA to tumor necrosis factor inhibitors (TNFi) who had an exceptional improvement after administration of the interleukin-17A inhibitor (IL-17Ai) secukinumab.

Keywords: IL-17A inhibitor; Psoriatic arthritis; Secukinumab; TNF inhibitors.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
a Skin involvement while on etanercept. b Marked improvement on week 4 of secukinumab administration. c Significant improvement on week 36 of secukinumab administration
See this image and copyright information in PMC

References

    1. Nikas SN, Voulgari PV, Takalou IP, Katsimbri P, Drosos AA. Healing of psoriatic skin lesions, and improvement of psoriatic arthritis resistant to immunosuppressive drugs, after infliximab treatment. Ann Rheum Dis. 2005;64(11):1665–1667. doi: 10.1136/ard.2005.036178. - DOI - PMC - PubMed
    1. Wollina U, Conrad H. Treatment of recalcitrant psoriatic arthritis with anti-tumor necrosis factor-alpha antibody. J Eur Acad Dermatol Venereol. 2002;16(2):127–129. doi: 10.1046/j.1468-3083.2002.00391.x. - DOI - PubMed
    1. Nash P, Clegg DO. Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis. 2005;64(Suppl ii):74-ii77. doi: 10.1136/ard.2004.030783. - DOI - PMC - PubMed
    1. de Vlam K, Lories RJ. Remission in psoriatic arthritis. Curr Rheumatol Rep. 2008;10(4):297–302. doi: 10.1007/s11926-008-0048-z. - DOI - PubMed
    1. Atteno M, Peluso R, Costa L, Padula S, Iervolino S, Caso F, Sanduzzi A, Lubrano E, et al. Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. Clin Rheumatol. 2010;29(4):399–403. doi: 10.1007/s10067-009-1340-7. - DOI - PubMed

LinkOut - more resources